Experienced leadership and clinical expertise create the partnerships that produce successful drug development outcomes.
Since 1986, Ockham Oncology has conducted more than 250 oncology trials across all phases of development, including pre-clinical preparation, in support of bringing innovative oncology therapies to market. In 2009, Ockham acquired a U.S.-based oncology CRO. Three years later, Ockham expanded its clinical expertise and global footprint with the acquisition of Scotland-based Nexus Oncology.
Ockham Source, our full-spectrum global resourcing solution, provides a complementary capability to our clients. One that provides superior expertise with a level of communication, service and dedication that is unique in our industry.
Our focus, our commitment and our energy result in an acute understanding of cancer – and a real passion to fight it. We also understand the need for adaptability in an ever-changing environment. Adhering to proven methods while maintaining adaptability provides a closer link to discovering solutions.
At Ockham Oncology, our team members average more than 10 years of direct experience working with both the challenges and opportunities that oncology requires. As part of our commitment to growth, Ockham Oncology has successfully expanded its expertise beyond phases I-III and into IV.
The leading oncologists and thought leaders serving on Ockham Oncology’s Scientific Advisory Board are dedicated to bringing promising oncology therapies to market. Their global collaboration with leading oncology centers across Europe and North America have earned respect and recognition around the globe for Ockham’s drug development effort.
Driven by outcome. Defined by expertise. Ockham’s global reach and proven methods yield success in designing and managing clinical trials serving the oncology market.